Baxter International

BAX

Market cap $11.9B

Overview Fund Activity

23.20 USD

-0.67

2.81%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

23.41

+0.21

0.91%

1 day

-2.81%

5 days

-3.09%

1 month

-1.74%

3 months

-22.46%

6 months

-33.43%

Year to date

-20.71%

1 year

-41.72%

5 years

-71.82%

10 years

-36.18%

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 38,000

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

136% more call options, than puts

Call options by funds: $119M | Put options by funds: $50.4M

1.63% more ownership

Funds ownership: 94.83% [Q1] → 96.46% (+1.63%) [Q2]

8% less funds holding

Funds holding: 825 [Q1] → 756 (-69) [Q2]

10% less capital invested

Capital invested by funds: $16.7B [Q1] → $15B (-$1.66B) [Q2]

13% less repeat investments, than reductions

Existing positions increased: 255 | Existing positions reduced: 294

29% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]

44% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 124

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$24

3% upside

Avg. target

$30

29% upside

High target

$42

81% upside

7 analyst ratings

2 positive

29%

4 neutral

57%

1 negative

14%

Barclays Matt Miksic	$36	Overweight Maintained	4 Aug 2025
Stifel Rick Wise	$25	Hold Downgraded	4 Aug 2025
UBS Danielle Antalffy	$24	Neutral Maintained	4 Aug 2025
Wells Fargo Larry Biegelsen	$24	Equal-Weight Maintained	1 Aug 2025
Morgan Stanley Patrick Wood	$27	Underweight Maintained	15 Jul 2025
Citigroup Joanne Wuensch	$32	Neutral Maintained	9 Jul 2025
Evercore ISI Group Vijay Kumar	$42	Outperform Maintained	8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Baxter Launches Welch Allyn Connex 360 Vital Signs Monitor to Advance Connected Patient Monitoring

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, today launched the Welch Allyn Connex 360 Vital Signs Monitor, its next generation patient monitoring device. As the latest innovation in Baxter's connected monitoring portfolio, Connex 360 offers an advanced connectivity and security platform, customizable configurations based on a hospital's clinical routines, and upgrade capabilities that set the stage for future functionality and enhanc.

Baxter Launches Welch Allyn Connex 360 Vital Signs Monitor to Advance Connected Patient Monitoring

Is Now The Time To Buy Baxter Stock?

Baxter stock (NYSE: BAX), a healthcare company, has seen its stock decline by 14% over the past month. This drop followed a disappointing earnings report where the company also reduced its full-year guidance, partly due to Hurricane Helene impacting one of its manufacturing facilities.

Is Now The Time To Buy Baxter Stock?

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

CNBC Television

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

President Trump demands drugmakers slash prices within 60 days

The Motley Fool

Baxter (BAX) Q2 Revenue Rises 4%

Baxter (BAX) Q2 Revenue Rises 4%

Baxter (BAX) Q2 Revenue Rises 4%

Hospital Product Maker Baxter Stock Plunges On Trimmed Annual Outlook

Q2 adjusted EPS was $0.59, matching guidance but slightly below the $0.61 Street estimate. FY25 EPS forecast lowered to $2.42–$2.52 vs. prior range of $2.47–$2.55.

Hospital Product Maker Baxter Stock Plunges On Trimmed Annual Outlook

Zacks Investment Research

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

Baxter International (BAX) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.68 per share a year ago.

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

Zacks Investment Research

BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down

Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.

BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down

Baxter International Inc. (BAX) Q2 2025 Earnings Call Transcript

Baxter International Inc. (NYSE:BAX ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Clare Trachtman - Vice President of Investor Relations David Brent Shafer - Chair & Interim CEO Heather Knight - Executive Vice President & COO Joel T. Grade - Executive VP & CFO Conference Call Participants David Harrison Roman - Goldman Sachs Group, Inc., Research Division Lawrence H.

Baxter International Inc. (BAX) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™